Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887781 | 1.00 | MAP2K1 (0.43) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL14342038 | 0.91 | MAP2K1 (0.54) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL3874109 | 0.90 | MAP2K1 (0.49) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL3874114 | 0.90 | MAP2K1 (0.49) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL5486087 | 0.83 | MAP2K1 (0.62) | MAP2K1MAP2K2 | |
| SCHEMBL5486091 | 0.83 | MAP2K1 (0.62) | MAP2K1MAP2K2 | |
| SCHEMBL13686525 | 0.82 | MAP2K1 (0.47) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL3875114 | 0.82 | MAP2K1 (0.38) | MAP2K1MAP2K2 | |
| SCHEMBL3877145 | 0.79 | MEN1 (0.42) | MAP2K1MAP2K2 | |
| SCHEMBL14342036 | 0.73 | MAP2K1 (0.45) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828184-B1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | MERCK SERONO SA (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20070299103-A1 | [1,2,4]Triazolo[4,3-A]Pyridine Derivatives for the Treatment of Hyperproliferative Diseases | MERCK SERONO SA (CH) | 2007-12-27 | — | — | US | disclosed |
| EP-1828184-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | LABORATOIRES SERONO S.A. (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058752-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | LABORATOIRES SERONO S.A. (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299103-A1 | [1,2,4]Triazolo[4,3-A]Pyridine Derivatives for the Treatment of Hyperproliferative Diseases | CDK4, CDK3, BRAF | MAP2K1 114/4885MAP2K2 117/4885BRAF 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.